Orthostatic hypotension (OH) is common in older people and is associated with a range of adverse outcomes. Although agerelated changes like decreased baroreflex sensitivity make older people prone to OH, medications are often a contributor. Diagnosis of OH can be challenging in older people, because the condition may present with atypical or non-specific symptoms, such as visual disturbances, shortness of breath, mental fluctuation. Non-pharmacological management is often a starting point for OH treatment. Fludrocortisone and midodrine remain the most studied drugs for pharmacological management, but newer agents are being tested. In this review we present the current evidence for existing and emerging treatments for OH and address the management of supine hypertension associated with the treatment of OH in patients with autonomic failure. In the management of OH, it is imperative that treatment is tailored to the individual, rather than focusing on attaining an arbitrary blood pressure target.
INTRODUCTION
Orthostatic hypotension (OH) is common in older adults, and its incidence increases with age. 1 OH is an important cause of syncope and falls, and may contribute to morbidity, all-cause mortality and reduced quality of life. 2 Patients with OH may develop coronary events, stroke and have a poor prognosis, especially if they have comorbidities such as diabetes and Parkinson's disease.
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DEFINITION
The latest consensus statement published in 2011 defines OH as a drop in blood pressure (BP) of at least 20 mmHg for systolic BP (SBP) or 10 mmHg for diastolic BP (DBP) within 3 min of standing or during a head-up tilt test to at least 60°. 6 In patients with hypertension (supine SBP ≥160 mmHg), a more appropriate criterion for the diagnosis of OH would be a drop in SBP of at least 30 mmHg. 5, 6 The 2011 consensus statement also identifies two variants of OH: initial OH and delayed OH. 6 In initial OH, there is an exaggerated transient fall in BP (>40 mmHg SBP and/or 20 mmHg DBP) accompanied by symptoms of hypoperfusion within 15 s of standing. Initial OH may occur during active standing and, to a lesser extent, with passive tilting. In delayed OH, symptoms occur beyond 3 min of standing. The clinical significance of this latter form of OH is not well defined, but may reveal an early or mild form of sympathetic adrenergic failure. 7, 8 In clinical practice, when using intermittent BP measurements, the first measurement should be taken 30 s after standing, and the second measurement at 60 s. 3, 5 This is because the nadir of BP drop usually occurs within 30-60 s. 3 Subsequent measurements should be taken at 1-min intervals, usually for a total of 3 min. In patients with suspected neurogenic OH, extending the test to up to 10 min may be helpful to check for delayed OH.
PREVALENCE AND IMPLICATIONS
The prevalence of OH in community-dwelling older people has been reported to vary between 9% and 34%. 9, 10 In the Cardiovascular Health Study, 11 of 5201
American men and women aged over 65 years, 16 .2% had asymptomatic OH. Another 2.0% had symptomatic OH presenting as dizziness, light headedness or faintness. 11, 12 In aged care facilities and acute hospital settings, OH prevalence as high as 50% has been reported. 3 It has also been reported that OH affects 25% of patients with type 2 diabetes mellitus (T2DM) and 70% of patients with Parkinson's disease. 5 Several studies have shown that OH is an independent risk factor for morbidity and mortality, 13, 14 and a decline in SBP >20 mmHg is a risk factor for falls, especially in older patients with hypertension. Older people with OH are most likely to be physically frail with decreased functional capacity. OH is often overlooked as a cause of frailty in older patients in whom orthostatic vital signs are rarely obtained. 15 OH in the older adult may increase the risk of cerebral hypoxic changes leading to cognitive decline and dementia. 16 It is therefore recommended that BP monitoring, including orthostatic testing, be routinely performed in this population. 16 OH also increases the risk of cardiovascular disease and all-cause mortality in older people, and is associated with syncope, falls and fractures, which may lead to functional impairment and hospitalisation. 17 
PATHOPHYSIOLOGY OF OH
When a healthy person stands, approximately 700 mL blood pools below the diaphragm and results in decreased venous return to the heart, reduced ventricular filling and a transient decrease in cardiac output. 18 The consequent baroreflex-mediated sympathetic activation, along with parasympathetic withdrawal, results in increased heart rate, stroke volume and peripheral vasoconstriction, maintaining BP. In a healthy subject, this orthostatic stabilisation is normally achieved within 1 min of standing. A failure of any of these systems can lead to OH. 11, 19, 20 Aging-related changes, like decreased baroreflex sensitivity, which manifests as decreased heart rate and a 1 -adrenoceptor vasoconstrictor response to sympathetic stimuli upon standing, can make older people prone to OH. 18 A reduction in renal salt and water conservation and cardiac filling also increase the risk of OH in older people. 18 
SYMPTOMS OF OH
Clinical manifestations are due to hypoperfusion or overcompensation. Symptoms related to cerebral hypoperfusion include light-headedness, dizziness, weakness, difficulty thinking and feeling faint. Compensatory autonomic overreaction can cause palpitations, tremulousness, nausea, coldness of extremities and chest pain. 21 There is not always a correlation between the fall in BP and the symptoms of OH. Up to 80% of patients with OH may be asymptomatic. Some patients may present with symptoms not usually attributed to OH, like shortness of breath, chest pain, seizures or dizziness after a meal (post-meal syncope). 2 Patients with dementia may present with mental fluctuations, confusion, drowsiness and falls. 22 Other atypical symptoms of OH can include dim, blurred or tunnel vision, or a dull pain in the back of the neck and shoulder (coat hanger distribution) induced by reduced muscular flow.
14, 15 The circumstances in which symptoms occur must be carefully analysed in order to identify OH as a possible cause. 14 
CAUSES OF OH
Causes of OH can be broadly classified into neurogenic and non-neurogenic (Table 1) . A peripheral or central neurological lesion can cause autonomic dysfunction and a failure to correct for transient falls in BP upon standing. 13 Multisystem atrophy (MSA) is a central disorder that causes autonomic dysfunction. Peripheral causes include neurodegenerative disorders like Parkinson's disease and pure autonomic failure (PAF). 13, 23 OH can also be observed as secondary autonomic insufficiency in conditions such as diabetes and amyloidosis. 13, 23 Medications represent a major non-neurogenic cause of OH. The main culprits are antihypertensive medications, in particular beta-blockers 24 and a-adrenoceptor antagonists (including those prescribed for urinary disorders), vasodilators, diuretics, antiparkinsonian drugs and some antipsychotics (most antipsychotics have a propensity to cause OH, but OH is more prevalent with clozapine and olanzapine). [25] [26] [27] In a study conducted at a US Veterans Affairs geriatric clinic, the prevalence of OH in patients receiving zero, one, two and three or more potentially causative medications was 35%, 58%, 60% and 65%, respectively. 28 The ACTION (A large-scale open-label clinical experience trial) study investigators found that antihypertensive drugs that act on the renin-angiotensin system were well tolerated in older people. 29 Significant postural falls in BP can be associated with meals (postprandial OH), especially after consumption of a large meal high in carbohydrates, due to gastric distension, release of vasodilatory peptides and splanchnic blood pooling. 6, 14 Genetic predisposition towards OH has not been comprehensively explored. 23 Long periods of immobilisation, such as during a hospital stay, can also make older patients more susceptible to OH .
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Reduced cardiac filling (due to an increase in heart stiffness) and a reduction in renal salt and water conservation during periods of fluid restriction or volume loss (due to reduced renin, angiotensin and aldosterone and increased natriuretic peptides) also increase the risk of hypotension in older people. 18 OH is more common and more severe in the morning, most likely due to nocturnal supine hypertension, which causes a pressure diuresis. This may cause significant intravascular volume loss overnight, thus increasing the risk of morning hypotension. 6, 30 
MANAGEMENT GOALS
The treatment of OH should be directed towards ameliorating the symptoms, correcting any underlying cause, improving functional status and reducing the risk of complications rather than aiming for an arbitrary BP goal. 18 Using relative decreases in BP to guide treatment may be more appropriate in clinical practice. 31 With the exception of a ≥ 25% decrease in SBP or DBP, the clinical relevance of asymptomatic OH BP measurements (identified on OH screening) seems very limited with regard to orthostatic complaints or fall incidents. Each patient must have an individualised treatment plan that is reassessed and modified on a regular basis to ascertain benefit and side effects of the current regimen. 2 
MANAGEMENT OF OH
Diagnosis of OH in older people is often challenging because of comorbid conditions and non-specific OH symptomatology. Initial management should always include screening for acute precipitants, such as medications and hypovolaemia. A thorough medication history is of paramount importance in identifying drug causes of OH. Management of OH can be broadly classified into non-pharmacological and pharmacological interventions.
Non-pharmacological Measures
Non-pharmacological measures, including patient education, should be the first line of treatment.
3,30 A systematic review identified physical and dietary measures as two major non-pharmacological treatment categories. 32 Physical measures include compression stockings (abdominal or lower limbs), exercise, physical counter-manoeuvres and sleeping with the head elevated. Dietary measures to limit postprandial OH include eating small, frequent meals low in rapidly absorbed carbohydrate. 14, 32 Adequate hydration, by drinking one to two large glasses of water before each meal, helps limit postprandial hypotension associated with neurogenic OH.
14 Elevating the head and neck during the night (>10°) can activate the carotid and aortic baroreceptors and renin-angiotensin-aldosterone system to control supine hypertension and reduce early morning hypotension. 14 When rising from a bed, patients should be advised to move to a head-up position slowly and to sit on edge of the bed for a few minutes prior to standing. Activating the calf muscles while supine, prior to rising, also helps.
Patients who do not respond to simple measures may benefit from physical counter manoeuvres (e.g. crossing the legs while standing, squatting, marching in place), which cause compression of splanchnic vessels, increase abdominal pressure, venous return and reduce blood pooling. 4 However, this can be challenging for some because it requires a certain level of mobility and balance. 2, 4, 32 In older people with OH due to deconditioning, an exercise regimen including swimming or recumbent biking may also help attenuate symptoms.
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Some observational studies have suggested that abdominal support garments are better at preventing OH than leg garments. 33 Limb and abdominal compression may improve orthostatic tolerance in up to 40% of patients. The recommended compression pressure is 30-50 mmHg for leg compression and 20-30 mmHg for abdominal compression. 30 Although they are inconvenient to apply and can be uncomfortable during warm weather, the positive effects of support garments are often recognised by the patient and can be used as needed when a prolonged orthostatic challenge is expected. 30 Volume expansion by increased salt and fluid remains a cornerstone in patients with OH and no contraindications. Caution should be exercised in patients with heart or kidney failure and supine hypertension. 23, 34 The pressor response of water takes 5-10 min to start, peaks between 20 and 40 min after ingestion and starts to wane by 60 min. 13 A bolus of two glasses of 240 mL water in rapid succession improves SBP by 20 mmHg. 3 If this fails to attenuate the symptoms, patients should be encouraged to increase salt intake up to 6-10 g/day and water intake to 1.5-2.0 L/day. 35 Sodium excretion >170 mmol/day confirms adequate salt intake. 3 Antihypertensive medication withdrawal remains controversial, and recent clinical trials have done little to clear the uncertainty. 5 Treatment of OH requires balancing the risks of hypertension against the potential hypotensive effects of medications. 3 In patients with established OH and at risk of falls, aggressive BP-lowering treatment should be avoided. The revision of hypertension treatment targets to SBP of 140-150 mmHg should be considered. 14 Withdrawal of provoking agents (Table 1 ) may be helpful if they are suspected as a cause of OH. 5 The 2018 European Society of Cardiology (ESC) guidelines for the diagnosis and management of syncope outline the evidence behind non-pharmacological treatments (Table 2) . 36 A multidisciplinary team consisting of pharmacists, nurses and medical personnel can positively impact management of this challenging condition in older adults. 
Fludrocortisone
Fludrocortisone acetate is a synthetic mineralocorticoid with minimal glucocorticoid effects. It increases renal sodium retention and expands plasma volume. After oral administration, fludrocortisone is readily absorbed and peak plasma levels are reached within 45 min with a half-life of approximately 7 h. 4 The effect of fludrocortisone on plasma volume is transient. Its long-term effect may be related to potentiation of the pressor effect of angiotensin II and noradrenaline. 15 The 2018 ESC guidelines recommend a dose of 0.1-0.3 mg fludrocortisone once daily. 36 Higher doses, ranging from 0.2 mg twice daily to a maximum of 1 mg/day, have been used but need to be used with caution and under specialist supervision. 2,18,20,21 Doses higher than 0.1-0.3 mg daily should be avoided in those with hypoalbuminaemia and congestive heart failure. 5 Higher doses of fludrocortisone can result in supine hypertension and severe hypokalaemia. At higher doses, patients may be at an increased risk of hypothalamic-pituitaryadrenal axis suppression. 13 Headaches can occur, especially while supine. 4 Peripheral oedema is another common side effect of fludrocortisone. It is important to review the concomitant use of medications, such as diuretics, because volume depletion may render fludrocortisone ineffective. Evidence for fludrocortisone is from two small observational studies (in combination with head-up sleeping) and one double-blind trial in 60 patients. 36 The observational studies demonstrated haemodynamic benefit. In the trial, treated patients were less symptomatic with a higher BP. The quality of evidence is moderate and further research is likely to have an important effect on the estimate of benefit. 36 The 2018 ESC guidelines conclude that fludrocortisone should be used when OH symptoms persist. 36 
Midodrine
Midodrine is a peripherally acting selective a 1 -adrenoceptor agonist that stimulates arterial and venous adrenoceptors. Midodrine increases BP via vasoconstriction. 4 Midodrine is a useful addition in patients with chronic autonomic failure. 3, 36, 38 It may be preferred over fludrocortisone for patients with OH and pre-existing supine hypertension or heart failure, because it does not produce excessive fluid retention. 13, 15 Vasoconstrictors such as midodrine are ineffective when plasma volume is reduced. 16 Midodrine does not cross the blood-brain barrier and does not increase heart rate. 15 It is a prodrug that is rapidly converted to desglymidodrine, which has a short half-life and a duration of action of approximately 3-4 h. 13 Midodrine is excreted mainly in urine. 15 Given the short half-life of midodrine, the dosing schedule is typically three times a day, with the first dose taken half an hour prior to mobilisation in the morning. Patients should be instructed to take the last dose at least 4-5 h before bedtime to avoid supine hypertension, which occurs in 25% of users. 5, 13 Doses of midodrine typically start at 2.5 mg once or twice per day, increased as required to 10 mg three times a day. 5 The manufacturer recommends avoiding the use of midodrine in severe renal impairment (estimated glomerular filtration rate <30 mL/min per 1.73 m 2 ), but the Renal Drug Handbook recommends it for treatment of dialysis-related OH. 39 Side effects of midodrine include supine hypertension, piloerection (goose bumps), scalp tingling, urinary urgency or retention and, rarely, headaches. Caution should be exercised when using midodrine in patients with acute kidney injury, liver disease, severe heart disease, thyrotoxicosis and phaeochromocytoma. 5, 14 Occasional side effects such as insomnia and irritability have also been reported. 14 Some patients' OH worsens on midodrine and the mechanism is thought to be adrenoceptor desensitisation. 39 Evidence for the use of midodrine is conflicting. A meta-analysis in 2014 suggested a lack of evidence. 39 This is in contrast with other reviews that have reported that the use of midodrine in neurogenic OH does reach a strong recommendation level. [40] [41] [42] According to 2018 ESC guidelines, 36 midodrine is not helpful in all patients, but it is very useful in some. The desirable effects of midodrine outweigh the undesirable effects in patients with chronic autonomic failure. 36 Midodrine certainly increases BP in both the supine and upright positions and ameliorates the symptoms of OH. Midodrine is not marketed in Australia, but is available via the Therapeutic Goods Administration (TGA) Special Access Scheme. Combination therapy with fludrocortisone and midodrine, using lower doses of both agents (due to synergistic effects), may be beneficial in refractory patients. 15, 18, 38, 43 Pyridostigmine Pyridostigmine is a cholinesterase inhibitor that improves neurotransmission at acetylcholine-mediated neurons of the autonomic nervous system. 44 Pyridostigmine improves OH and total peripheral resistance without aggravating supine hypertension. 21 Because the pressor effect of pyridostigmine is modest, it is adequate in patients with mild to moderate OH of neurogenic origin. 45 The usual starting dose of pyridostigmine is 30 mg twice a day, which can be slowly titrated up to 90 mg three times a day. 34 Side effects include nausea, diarrhoea, urinary urgency, diaphoresis, hyper salivation and fasciculations. 13, 34, 44 Contraindications include hypersensitivity to bromides or pyridostigmine and urinary obstruction. 46 Pyridostigmine has been shown to improve OH compared with placebo. 47 However, there is a need for robust studies in older people to confirm its effectiveness and tolerability in this population. A randomised trial comparing pyridostigmine to fludrocortisone in the treatment of OH in Parkinson's disease concluded that pyridostigmine was inferior to fludrocortisone. 44 The evidence supporting the use of pyridostigmine is conflicting at best, and hence the recommendation for its use is weak.
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Droxidopa
Droxidopa is a synthetic amino acid precursor that is converted by aromatic L-amino acid decarboxylase into noradrenaline. Droxidopa acts to increase levels of noradrenaline in postganglionic sympathetic neurons, leading to increased stimulation of adrenoceptors and hence increased BP. 49 Droxidopa has a short half-life of 2-3 h and should be avoided within 5 h of bedtime to avoid supine hypertension. 3 Evidence for droxidopa is promising, but long-term data on its use are limited. 40 Droxidopa has been used in Japan since 1989, but has only recently been approved for OH in the US and UK. It is not yet approved in Australia, but can be obtained under the TGA Special Access Scheme. Possible side effects of droxidopa include hypertension, headache, dizziness, nausea, falls and urinary tract infections. 50 Syncope and dizziness have also been reported, although systematic post-marketing studies to define the rate of adverse events in clinical practice are not available. 51 A systematic review exploring the effect of droxidopa compared with midodrine on standing BP and orthostatic tolerance in adults with neurogenic orthostatic hypotension is underway. 52 Because the evidence for droxidopa is limited, and due to a lack of long-term data on safety, it has not been included in the current ESC guidelines.
Other Medications
Numerous other medications have been considered for the management of OH and may be useful in selected patients. These are summarised in Table 3 .
SUPINE HYPERTENSION WITH OH
Patients with autonomic failure often experience both neurogenic OH and severe nocturnal supine hypertension. 14, 53, 54 This is a clinical dilemma for clinicians because they must balance the risk of chronic high BP with the risk of falls and increased morbidity associated with OH. 53 In these cases, fludrocortisone should be limited and using evening short-acting antihypertensive agents may be considered. However, the long-term cardiovascular risk associated with supine hypertension is not well known, and the decision to treat should be tailored to individual patient needs. If the patient is not at high risk of falls, and BP-lowering therapy is warranted, angiotensin-converting enzyme inhibitors (short-acting agents such as captopril), angiotensin receptor blockers (such as losartan) and calcium channel blockers (such as nifedipine) are preferred. The use of glyceryl trinitrate (GTN) patches (with removal 1 h before rising), hydralazine and minoxidil has been investigated. 3 Although the use of GTN patches is fairly common, the evidence supporting their use is limited. Pindolol may be effective due to its limited effect on daytime OH (because of its intrinsic sympathomimetic effect), but robust evidence is lacking. 3 In general, 24-h ambulatory BP monitoring should be performed first, and night-time administration of antihypertensive doses is preferred, even if the patient is treated for ischemic heart disease or heart failure.
Diuretics and beta-blockers should be avoided, if possible, because they are associated with OH and falls. 30 
CONCLUSION
The evidence to support the effectiveness of pharmacological measures in older people with OH is limited. Non-pharmacological strategies, including discontinuation or reduction of vasoactive drugs, need to be explored before choosing medications to treat OH. 36 Drugs generally recommended for OH treatment are fludrocortisone and/or midodrine, with due consideration of their precautions. There are systematic reviews currently underway 55 that will hopefully provide more robust evidence. Meanwhile, it is important to tailor treatment based on individual presentation and needs.
